EyePoint’s Age-Related Eye Disease Drug Fails Late-Stage Trial, Plunging Shares by 70%

EyePoint Pharmaceuticals encountered a significant setback as its experimental drug, Duravyu, failed to demonstrate efficacy in a late-stage trial for treating wet age-related macular degeneration, a prevalent cause of vision impairment among the elderly. The company’s shares plummeted over 65% in premarket trading following the announcement, illustrating the market’s immediate negative reaction to the trial’s results. EyePoint was endeavoring to position Duravyu as a formidable competitor to Regeneron’s Eylea, which not only dominates the market but also generated formidable sales of $4.39 billion in the U.S. last year.

The company’s assertion that the trial’s overall results were skewed by nine patients who experienced unrelated vision loss provides a critical context; however, this explanation may not suffice to alleviate investor concerns. Mizuho analyst Graig Suvannavejh indicated that investor sentiments are likely to remain cautious unless corroborated by subsequent studies. Conversely, TD Cowen analyst Tara Bancroft reinforced that the drug’s future approval now heavily relies on the outcomes of an additional trial expected later this year, emphasizing the precarious position EyePoint finds itself in as it seeks regulatory approval.

Despite the trial’s failure, EyePoint highlighted a key benefit of Duravyu: it significantly reduced the treatment burden for patients by cutting the average number of required injections by 42% compared to standard therapies. This reduction could appeal to both patients and healthcare providers, potentially enhancing Duravyu’s market positioning if future trials yield positive results. As the company moves forward with its plans to file for U.S. FDA approval in the first half of 2027, Wealthova investors will need to closely monitor the outcomes of the impending trials to assess the viability and future prospects of EyePoint’s offerings in a competitive landscape.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)